Ignite Creation Date:
2024-07-17 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06500208
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-07-06
Brief Title:
Neoadjuvant Adebrelimab and Chemotherapy in High-rish ERHER2- BC
Sponsor:
Shanghai Jiao Tong University School of Medicine
Organization:
Shanghai Jiao Tong University School of Medicine
Study Overview
Official Title:
An Open-label One-arm Phase II Study of Adebrelimab Combined With Neoadjuvant Chemotherapy for High-risk Early-stage and Locally Advanced Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative ERHER2- Breast Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Investigators plan to conduct a single-arm clinical study of adebelimab a novel PD-L1 inhibitor in the neoadjuvant treatment of early or locally advanced high-risk ERHER2- breast cancer to explore whether the addition of immune checkpoint inhibitors to traditional neoadjuvant chemotherapy can improve the pathologic complete response rate pCR of patients evaluate its therapeutic safety and further analyze the biomarkers of the efficacy of neoadjuvant immunotherapy for ERHER2- breast cancer so as to support the clinical application of the drug
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None